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Introduction {#sec1}
============

Several members of the family *Coronaviridae* constantly circulate in the human population and usually cause mild respiratory disease ([@bib8]). In contrast, the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) are transmitted from animals to humans and cause severe respiratory diseases in afflicted individuals, SARS and MERS, respectively ([@bib12]). SARS emerged in 2002 in Guangdong province, China, and its subsequent global spread was associated with 8,096 cases and 774 deaths ([@bib10], [@bib52]). Chinese horseshoe bats serve as natural reservoir hosts for SARS-CoV ([@bib33], [@bib35]). Human transmission was facilitated by intermediate hosts like civet cats and raccoon dogs, which are frequently sold as food sources in Chinese wet markets ([@bib17]). At present, no specific antivirals or approved vaccines are available to combat SARS, and the SARS pandemic in 2002 and 2003 was finally stopped by conventional control measures, including travel restrictions and patient isolation.

In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China ([@bib25], [@bib51], [@bib61]). An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact. Subsequently, human-to-human transmission occurred ([@bib7]) and the disease, now termed coronavirus disease 19 (COVID-19) rapidly spread within China. A novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), which is closely related to SARS-CoV, was detected in patients and is believed to be the etiologic agent of the new lung disease ([@bib61]). On February 12, 2020, a total of 44,730 laboratory-confirmed infections were reported in China, including 8,204 severe cases and 1,114 deaths ([@bib53]). Infections were also detected in 24 countries outside China and were associated with international travel. At present, it is unknown whether the sequence similarities between SARS-CoV-2 and SARS-CoV translate into similar biological properties, including pandemic potential ([@bib42]).

The spike (S) protein of coronaviruses facilitates viral entry into target cells. Entry depends on binding of the surface unit, S1, of the S protein to a cellular receptor, which facilitates viral attachment to the surface of target cells. In addition, entry requires S protein priming by cellular proteases, which entails S protein cleavage at the S1/S2 and the S2' site and allows fusion of viral and cellular membranes, a process driven by the S2 subunit ([Figure 1](#fig1){ref-type="fig"} A). SARS-S engages angiotensin-converting enzyme 2 (ACE2) as the entry receptor ([@bib34]) and employs the cellular serine protease TMPRSS2 for S protein priming ([@bib15], [@bib40], [@bib49]). The SARS-S/ACE2 interface has been elucidated at the atomic level, and the efficiency of ACE2 usage was found to be a key determinant of SARS-CoV transmissibility ([@bib35], [@bib36]). SARS-S und SARS-2-S share ∼76% amino acid identity. However, it is unknown whether SARS-2-S like SARS-S employs ACE2 and TMPRSS2 for host cell entry.Figure 1SARS-2-S and SARS-S Facilitate Entry into a Similar Panel of Mammalian Cell Lines(A) Schematic illustration of SARS-S including functional domains (RBD, receptor binding domain; RBM, receptor binding motif; TD, transmembrane domain) and proteolytic cleavage sites (S1/S2, S2′). Amino acid sequences around the two protease recognition sites (red) are indicated for SARS-S and SARS-2-S (asterisks indicate conserved residues). Arrow heads indicate the cleavage site.(B) Analysis of SARS-2-S expression (upper panel) and pseudotype incorporation (lower panel) by western blot using an antibody directed against the C-terminal hemagglutinin (HA) tag added to the viral S proteins analyzed. Shown are representative blots from three experiments. β-Actin (cell lysates) and VSV-M (particles) served as loading controls (M, matrix protein). Black arrow heads indicate bands corresponding to uncleaved S proteins (S0) whereas gray arrow heads indicate bands corresponding to the S2 subunit.(C) Cell lines of human and animal origin were inoculated with pseudotyped VSV harboring VSV-G, SARS-S, or SARS-2-S. At 16 h postinoculation, pseudotype entry was analyzed by determining luciferase activity in cell lysates. Signals obtained for particles bearing no envelope protein were used for normalization. The average of three independent experiments is shown. Error bars indicate SEM. Unprocessed data from a single experiment are presented in [Figure S1](#figs1){ref-type="fig"}.

Results {#sec2}
=======

Evidence for Efficient Proteolytic Processing of SARS-2-S {#sec2.1}
---------------------------------------------------------

The goal of our study was to obtain insights into how SARS-2-S facilitates viral entry into target cells and how this process can be blocked. For this, we first asked whether SARS-2-S is robustly expressed in a human cell line, 293T, commonly used for experimentation because of its high transfectability. Moreover, we analyzed whether there is evidence for proteolytic processing of the S protein because certain coronavirus S proteins are cleaved by host cell proteases at the S1/S2 cleavage site in infected cells ([Figure 1](#fig1){ref-type="fig"}A). Immunoblot analysis of 293T cells expressing SARS-2-S protein with a C-terminal antigenic tag revealed a band with a molecular weight expected for unprocessed S protein (S0) ([Figure 1](#fig1){ref-type="fig"}B). A band with a size expected for the S2 subunit of the S protein was also observed in cells and, more prominently, in vesicular stomatitis virus (VSV) particles bearing SARS-2-S ([Figure 1](#fig1){ref-type="fig"}B). In contrast, an S2 signal was largely absent in cells and particles expressing SARS-S ([Figure 1](#fig1){ref-type="fig"}B), as previously documented ([@bib15], [@bib23]). These results suggest efficient proteolytic processing of SARS-2-S in human cells, in keeping with the presence of several arginine residues at the S1/S2 cleavage site of SARS-2-S but not SARS-S ([Figure 1](#fig1){ref-type="fig"}A). In contrast, the S2′ cleavage site of SARS-2-S was similar to that of SARS-S.

SARS-2-S and SARS-S Mediate Entry into a Similar Spectrum of Cell Lines {#sec2.2}
-----------------------------------------------------------------------

Replication-defective VSV particles bearing coronavirus S proteins faithfully reflect key aspects of coronavirus host cell entry ([@bib31]). We employed VSV pseudotypes bearing SARS-2-S to study cell entry of SARS-CoV-2. Both SARS-2-S and SARS-S were robustly incorporated into VSV particles ([Figure 1](#fig1){ref-type="fig"}B), allowing a meaningful side-by-side comparison; although, formally, comparable particle incorporation of the S1 subunit remains to be demonstrated. We first asked which cell lines were susceptible to SARS-2-S-driven entry, using a panel of well-characterized cell lines of human and animal origin, respectively. All cell lines were readily susceptible to entry driven by the glycoprotein of the pantropic VSV (VSV-G) ([Figure 1](#fig1){ref-type="fig"}C; [Figure S1](#figs1){ref-type="fig"} ), as expected. Most human cell lines and the animal cell lines Vero and MDCKII were also susceptible to entry driven by SARS-S ([Figure 1](#fig1){ref-type="fig"}C). Moreover, SARS-2-S facilitated entry into an identical spectrum of cell lines as SARS-S ([Figure 1](#fig1){ref-type="fig"}C), suggesting similarities in choice of entry receptors.Figure S1Representative Experiment Included in the Average, Related to [Figure 1](#fig1){ref-type="fig"}CThe indicated cells lines were inoculated with pseudoparticles harboring the indicated viral glycoprotein or harboring no glycoprotein (no protein) and luciferase activities in cell lysates were determined at 16 h posttransduction. The experiment was performed with quadruplicate samples, the average ± SD is shown.

SARS-CoV-2 Employs the SARS-CoV Receptor for Host Cell Entry {#sec2.3}
------------------------------------------------------------

In order to elucidate why SARS-S and SARS-2-S mediated entry into the same cell lines, we next determined whether SARS-2-S harbors amino acid residues required for interaction with the SARS-S entry receptor ACE2. Sequence analysis revealed that SARS-CoV-2 clusters with SARS-CoV-related viruses from bats (SARSr-CoV), of which some but not all can use ACE2 for host cell entry ([Figure 2](#fig2){ref-type="fig"} A; [Figure S2](#figs2){ref-type="fig"} ). Analysis of the receptor binding motif (RBM), a portion of the receptor binding domain (RBD) that makes contact with ACE2 ([@bib35]), revealed that most amino acid residues essential for ACE2 binding by SARS-S were conserved in SARS-2-S ([Figure 2](#fig2){ref-type="fig"}B). In contrast, most of these residues were absent from S proteins of SARSr-CoV previously found not to use ACE2 for entry ([Figure 2](#fig2){ref-type="fig"}B) ([@bib13], [@bib21], [@bib41]). In agreement with these findings, directed expression of human and bat (*Rhinolophus alcyone*) ACE2 but not human DPP4, the entry receptor used by MERS-CoV ([@bib45]), or human APN, the entry receptor used by HCoV-229E ([@bib58]), allowed SARS-2-S- and SARS-S-driven entry into otherwise non-susceptible BHK-21 cells ([Figure 3](#fig3){ref-type="fig"} A). Moreover, antiserum raised against human ACE2 blocked SARS-S- and SARS-2-S- but not VSV-G- or MERS-S-driven entry ([Figure 3](#fig3){ref-type="fig"}B). Finally, authentic SARS-CoV-2 infected BHK-21 cells transfected to express ACE2 cells but not parental BHK-21 cells with high efficiency ([Figure 3](#fig3){ref-type="fig"}C), indicating that SARS-2-S, like SARS-S, uses ACE2 for cellular entry.Figure 2SARS-2-S Harbors Amino Acid Residues Critical for ACE2 Binding(A) The S protein of SARS-CoV-2 clusters phylogenetically with S proteins of known bat-associated betacoronaviruses (see [Figure S2](#figs2){ref-type="fig"} for more details).(B) Alignment of the receptor binding motif of SARS-S with corresponding sequences of bat-associated betacoronavirus S proteins, which are able or unable to use ACE2 as cellular receptor, reveals that SARS-CoV-2 possesses crucial amino acid residues for ACE2 binding.Figure S2Extended Version of the Phylogenetic Tree, Related to [Figure 2](#fig2){ref-type="fig"}BFigure 3SARS-2-S Utilizes ACE2 as Cellular Receptor(A) BHK-21 cells transiently expressing ACE2 of human or bat origin, human APN, or human DPP4 were inoculated with pseudotyped VSV harboring VSV-G, SARS-S, SARS-2-S, MERS-S, or 229E-S. At 16 h postinoculation, pseudotype entry was analyzed (normalization against particles without viral envelope protein).(B) Untreated Vero cells as well as Vero cells pre-incubated with 2 or 20 μg/mL of anti-ACE2 antibody or unrelated control antibody (anti-DC-SIGN, 20 μg/mL) were inoculated with pseudotyped VSV harboring VSV-G, SARS-S, SARS-2-S, or MERS-S. At 16 h postinoculation, pseudotype entry was analyzed (normalization against untreated cells).(C) BHK-21 cells transfected with ACE2-encoding plasmid or control transfected with DsRed-encoding plasmid were infected with SARS-CoV-2 and washed, and genome equivalents in culture supernatants were determined by quantitative RT-PCR.The average of three independent experiments conducted with triplicate samples is shown in (A--C). Error bars indicate SEM. Statistical significance was tested by two-way ANOVA with Dunnett posttest. Cells transfected with empty vector served as reference in (A) whereas cells that were not treated with antibody served as reference in (B).

The Cellular Serine Protease TMPRSS2 Primes SARS-2-S for Entry, and a Serine Protease Inhibitor Blocks SARS-CoV-2 Infection of Lung Cells {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------------------------

We next investigated protease dependence of SARS-CoV-2 entry. SARS-CoV can use the endosomal cysteine proteases cathepsin B and L (CatB/L) ([@bib50]) and the serine protease TMPRSS2 ([@bib15], [@bib40], [@bib49]) for S protein priming in cell lines, and inhibition of both proteases is required for robust blockade of viral entry ([@bib28]). However, only TMPRSS2 activity is essential for viral spread and pathogenesis in the infected host whereas CatB/L activity is dispensable ([@bib27], [@bib47], [@bib48], [@bib59]).

In order to determine whether SARS-CoV-2 can use CatB/L for cell entry, we initially employed ammonium chloride, which elevates endosomal pH and thereby blocks CatB/L activity. 293T cells (TMPRSS2^−^, transfected to express ACE2 for robust S protein-driven entry) and Caco-2 cells (TMPRSS2^+^) were used as targets. Ammonium chloride blocked VSV-G-dependent entry into both cell lines whereas entry driven by Nipah virus F and G proteins was not affected ([Figure S3](#figs3){ref-type="fig"} A; data not shown), consistent with Nipah virus but not VSV being able to fuse directly with the plasma membrane ([@bib4]). Ammonium chloride treatment strongly inhibited SARS-2-S- and SARS-S-driven entry into TMPRSS2^−^ 293T cells ([Figure S3](#figs3){ref-type="fig"} A), suggesting CatB/L dependence. Inhibition of entry into TMPRSS2^+^ Caco-2 cells was less efficient compared to 293T cells ([Figure S3](#figs3){ref-type="fig"} A), which would be compatible with SARS-2-S priming by TMPRSS2 in Caco-2 cells. Indeed, the clinically proven serine protease inhibitor camostat mesylate, which is active against TMPRSS2 ([@bib28]), partially blocked SARS-2-S-driven entry into Caco-2 ([Figure S3](#figs3){ref-type="fig"} B) and Vero-TMPRSS2 cells ([Figure 4](#fig4){ref-type="fig"} A). Full inhibition was attained when camostat mesylate and E-64d, an inhibitor of CatB/L, were added ([Figure 4](#fig4){ref-type="fig"}A; [Figure S3](#figs3){ref-type="fig"}B), indicating that SARS-2-S can use both CatB/L as well as TMPRSS2 for priming in these cell lines. In contrast, camostat mesylate did not interfere with SARS-2-S-driven entry into the TMPRSS2^−^ cell lines 293T ([Figure S3](#figs3){ref-type="fig"}B) and Vero ([Figure 4](#fig4){ref-type="fig"}A), which was efficiently blocked by E-64d and therefore is CatB/L dependent. Moreover, directed expression of TMPRSS2 rescued SARS-2-S-driven entry from inhibition by E-64d ([Figure 4](#fig4){ref-type="fig"}B), confirming that SARS-2-S can employ TMPRSS2 for S protein priming.Figure S3Protease Requirement for SARS-2-S-Driven Entry and Absence of Unwanted Cytotoxicity of Camostat Mesylate, Related to [Figure 4](#fig4){ref-type="fig"}(A and B) Importance of endosomal low pH (A) and activity of CatB/L or TMPRSS2 (B) for host cell entry of SARS-CoV-2 was evaluated by adding inhibitors to target cells prior to transduction. Ammonium chloride (A) blocks endosomal acidification while E-64d and camostat mesylate (B) block the activity of CatB/L and TMPRSS2, respectively. Entry into cells not treated with inhibitor was set as 100%.(C) Absence of cytotoxic effects of camostat mesylate. Calu-3 cells were treated with camostat mesylate identically as for infection experiments and cell viability was measured using a commercially available assay (CellTiter-Glo, Promega).Figure 4SARS-2-S Employs TMPRSS2 for S Protein Priming in Human Lung Cells(A) Importance of activity of CatB/L or TMPRSS2 for host cell entry of SARS-CoV-2 was evaluated by adding inhibitors to target cells prior to transduction. E-64d and camostat mesylate block the activity of CatB/L and TMPRSS2, respectively (additional data for 293T cells transiently expressing ACE2 and Caco-2 cells are shown in [Figure S3](#figs3){ref-type="fig"}).(B) To analyze whether TMPRSS2 can rescue SARS-2-S-driven entry into cells that have low CatB/L activity, 293T cells transiently expressing ACE2 alone or in combination with TMPRSS2 were incubated with CatB/L inhibitor E-64d or DMSO as control and inoculated with pseudotypes bearing the indicated viral surface proteins.(C) Calu-3 cells were pre-incubated with the indicated concentrations of camostat mesylate and subsequently inoculated with pseudoparticles harboring the indicated viral glycoproteins.(D) Calu-3 cells were pre-incubated with camostat mesylate and infected with SARS-CoV-2. Subsequently, the cells were washed and genome equivalents in culture supernatants were determined by quantitative RT-PCR.(E) In order to investigate whether serine protease activity is required for SARS-2-S-driven entry into human lung cells, primary human airway epithelial cells were incubated with camostat mesylate prior to transduction.The average of three independent experiments conducted with triplicate or quadruplicate samples is shown in (A--E). Error bars indicate SEM. Statistical significance was tested by two-way ANOVA with Dunnett posttest. Cells that did not receive inhibitor served as reference in (A), (C), (D), and (E) whereas cells transfected with empty vector and not treated with inhibitor served as reference in (B).

We next analyzed whether TMPRSS2 usage is required for SARS-CoV-2 infection of lung cells. Indeed, camostat mesylate significantly reduced MERS-S-, SARS-S-, and SARS-2-S- but not VSV-G-driven entry into the lung cell line Calu-3 ([Figure 4](#fig4){ref-type="fig"}C) and exerted no unwanted cytotoxic effects ([Figure S3](#figs3){ref-type="fig"} C). Similarly, camostat mesylate treatment significantly reduced Calu-3 infection with authentic SARS-CoV-2 ([Figure 4](#fig4){ref-type="fig"}D). Finally, camostat mesylate treatment inhibited SARS-S- and SARS-2-S- but not VSV-G-driven entry into primary human lung cells ([Figure 4](#fig4){ref-type="fig"}E). Collectively, SARS-CoV-2 can use TMPRSS2 for S protein priming and camostat mesylate, an inhibitor of TMPRSS2, blocks SARS-CoV-2 infection of lung cells.

Evidence that Antibodies Raised against SARS-CoV Will Cross-Neutralize SARS-CoV-2 {#sec2.5}
---------------------------------------------------------------------------------

Convalescent SARS patients exhibit a neutralizing antibody response directed against the viral S protein ([@bib39]). We investigated whether such antibodies block SARS-2-S-driven entry. Four sera obtained from three convalescent SARS patients inhibited SARS-S- but not VSV-G-driven entry in a concentration-dependent manner ([Figure 5](#fig5){ref-type="fig"} ). In addition, these sera also reduced SARS-2-S-driven entry, although with lower efficiency compared to SARS-S ([Figure 5](#fig5){ref-type="fig"}). Similarly, rabbit sera raised against the S1 subunit of SARS-S reduced both SARS-S- and SARS-2-S-driven entry with high efficiency, and again inhibition of SARS-S-driven entry was more efficient. Thus, antibody responses raised against SARS-S during infection or vaccination might offer some level of protection against SARS-CoV-2 infection.Figure 5Sera from Convalescent SARS Patients Cross-Neutralize SARS-2-S-Driven EntryPseudotypes harboring the indicated viral surface proteins were incubated with different dilutions of sera from three convalescent SARS patients or sera from rabbits immunized with the S1 subunit of SARS-S and subsequently inoculated onto Vero cells in order to evaluate cross-neutralization potential. The average of three independent experiments performed with triplicate samples is shown. Error bars indicate SEM. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

Discussion {#sec3}
==========

The present study provides evidence that host cell entry of SARS-CoV-2 depends on the SARS-CoV receptor ACE2 and can be blocked by a clinically proven inhibitor of the cellular serine protease TMPRSS2, which is employed by SARS-CoV-2 for S protein priming. Moreover, it suggests that antibody responses raised against SARS-CoV could at least partially protect against SARS-CoV-2 infection. These results have important implications for our understanding of SARS-CoV-2 transmissibility and pathogenesis and reveal a target for therapeutic intervention.

The finding that SARS-2-S exploits ACE2 for entry, which was also reported by Zhou and colleagues ([@bib60]) while the present manuscript was in revision, suggests that the virus might target a similar spectrum of cells as SARS-CoV. In the lung, SARS-CoV infects mainly pneumocytes and macrophages ([@bib46]). However, ACE2 expression is not limited to the lung, and extrapulmonary spread of SARS-CoV in ACE2^+^ tissues was observed ([@bib11], [@bib16], [@bib19]). The same can be expected for SARS-CoV-2, although affinity of SARS-S and SARS-2-S for ACE2 remains to be compared. It has been suggested that the modest ACE2 expression in the upper respiratory tract ([@bib3], [@bib19]) might limit SARS-CoV transmissibility. In light of the potentially increased transmissibility of SARS-CoV-2 relative to SARS-CoV, one may speculate that the new virus might exploit cellular attachment-promoting factors with higher efficiency than SARS-CoV to ensure robust infection of ACE2^+^ cells in the upper respiratory tract. This could comprise binding to cellular glycans, a function ascribed to the S1 domain of certain coronaviruses ([@bib37], [@bib44]). Finally, it should be noted that ACE2 expression protects from lung injury and is downregulated by SARS-S ([@bib18], [@bib26], [@bib32]), which might promote SARS. It will thus be interesting to determine whether SARS-CoV-2 also interferes with ACE2 expression.

Priming of coronavirus S proteins by host cell proteases is essential for viral entry into cells and encompasses S protein cleavage at the S1/S2 and the S2′ sites. The S1/S2 cleavage site of SARS-2-S harbors several arginine residues (multibasic), which indicates high cleavability. Indeed, SARS-2-S was efficiently cleaved in cells, and cleaved S protein was incorporated into VSV particles. Notably, the cleavage site sequence can determine the zoonotic potential of coronaviruses ([@bib41], [@bib56], [@bib57]), and a multibasic cleavage site was not present in RaTG13, the coronavirus most closely related to SARS-CoV-2. It will thus be interesting to determine whether the presence of a multibasic cleavage site is required for SARS-CoV-2 entry into human cells and how this cleavage site was acquired.

The S proteins of SARS-CoV can use the endosomal cysteine proteases CatB/L for S protein priming in TMPRSS2^−^ cells ([@bib50]). However, S protein priming by TMPRSS2 but not CatB/L is essential for viral entry into primary target cells and for viral spread in the infected host ([@bib27], [@bib28], [@bib59]). The present study indicates that SARS-CoV-2 spread also depends on TMPRSS2 activity, although we note that SARS-CoV-2 infection of Calu-3 cells was inhibited but not abrogated by camostat mesylate, likely reflecting residual S protein priming by CatB/L. One can speculate that furin-mediated precleavage at the S1/S2 site in infected cells might promote subsequent TMPRSS2-dependent entry into target cells, as reported for MERS-CoV ([@bib30], [@bib43]). Collectively, our present findings and previous work highlight TMPRSS2 as a host cell factor that is critical for spread of several clinically relevant viruses, including influenza A viruses and coronaviruses ([@bib14], [@bib15], [@bib27], [@bib28], [@bib40], [@bib49], [@bib59]). In contrast, TMPRSS2 is dispensable for development and homeostasis ([@bib29]) and thus constitutes an attractive drug target. In this context, it is noteworthy that the serine protease inhibitor camostat mesylate, which blocks TMPRSS2 activity ([@bib28], [@bib59]), has been approved in Japan for human use, but for an unrelated indication. This compound or related ones with potentially increased antiviral activity ([@bib55]) could thus be considered for off-label treatment of SARS-CoV-2-infected patients.

Convalescent SARS patients exhibit a neutralizing antibody response that can be detected even 24 months after infection ([@bib39]) and that is largely directed against the S protein. Moreover, experimental SARS vaccines, including recombinant S protein ([@bib20]) and inactivated virus ([@bib38]), induce neutralizing antibody responses. Although confirmation with infectious virus is pending, our results indicate that neutralizing antibody responses raised against SARS-S could offer some protection against SARS-CoV-2 infection, which may have implications for outbreak control.

In sum, this study provided key insights into the first step of SARS-CoV-2 infection, viral entry into cells, and defined potential targets for antiviral intervention.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Monoclonal anti-HA antibody produced in mouseSigma-AldrichCat.\#: H3663;\
RRID: [AB_262051](nif-antibody:AB_262051){#intref0010}Monoclonal anti-β-actin antibody produced in mouseSigma-AldrichCat.\#: A5441;\
RRID: [AB_476744](nif-antibody:AB_476744){#intref0015}Monoclonal anti-VSV-M (23H12) antibodyKeraFastCat.\#: EB0011;\
RRID: [AB_2734773](nif-antibody:AB_2734773){#intref0020}Polyclonal anti-ACE2 antibodyR&D SystemsCat.\#: AF933;\
RRID: [AB_355722](nif-antibody:AB_355722){#intref0025}Polyclonal anti-DC-SIGN antibodySanta CruzCat.\#: sc-11038; RRID:[AB_639038](nif-antibody:AB_639038){#intref0030}Monoclonal anti-mouse, peroxidase-coupledDianovaCat.\#: 115-035-003;\
RRID:[AB_10015289](nif-antibody:AB_10015289){#intref0035}Anti-VSV-G antibody (I1, produced from CRL-2700 mouse hybridoma cells)ATCCCat.\# CRL-2700;\
RRID:CVCL_G654**Bacterial and Virus Strains**VSV^∗^ΔG-FLuc([@bib1])N/ASARS-CoV-2 isolate Munich 929Laboratory of Christian DrostenN/AOne Shot™ OmniMAX™ 2 T1R Chemically Competent *E. coli*ThermoFisher ScientificCat.\#: C854003**Biological Samples**Patient serum, CSS-2Laboratory of Christian DrostenN/APatient serum, CSS-3Laboratory of Andreas NitscheN/APatient serum, CSS-4Laboratory of Andreas NitscheN/APatient serum, CSS-5Laboratory of Andreas NitscheN/ARabbit serum, anti-SARS-S1 rabbit ILaboratory of Stefan PöhlmannN/ARabbit serum, anti-SARS-S1 rabbit IILaboratory of Stefan PöhlmannN/A**Chemicals, Peptides, and Recombinant Proteins**Camostat mesylateSigma-AldrichSML0057E-64dSigma-AldrichE8640Ammonium chlorideCarl RothCat.\#: 5050.2**Critical Commercial Assays**Beetle-Juice KitPJKCat.\#: 102511CellTiter-Glo® Luminescent Cell Viability AssayPromegaCat.\#: G7570**Experimental Models: Cell Lines**A549Laboratory of Georg HerrlerATCC Cat\# CRM-CCL-185;\
RRID:CVCL_0023BEAS-2BLaboratory of Stefan PöhlmannATCC Cat\# CRL-9609;\
RRID:CVCL_0168Calu-3Laboratory of Stephan LudwigATCC Cat\# HTB-55;\
RRID:CVCL_0609NCI-H1299Laboratory of Stefan PöhlmannATCC Cat\# CRL-5803;\
RRID:CVCL_0060Huh-7Laboratory of Thomas PietschmannJCRB Cat\# JCRB0403;\
RRID:CVCL_0336Caco-2Laboratory of Stefan PöhlmannATCC Cat\# HTB-37;\
RRID:CVCL_0025VeroLaboratory of Andrea MaisnerATCC Cat\# CRL-1586;\
RRID:CVCL_0574Vero-TMPRSS2This paperN/ALLC-PK1Laboratory of Georg HerrlerATCC Cat\# CRL-1392;\
RRID:CVCL_0391MDBKLaboratory of Georg HerrlerATCC Cat\# CCL-22;\
RRID:CVCL_0421MDCKIILaboratory of Georg HerrlerATCC Cat\# CRL-2936;\
RRID:CVCL_B034RhiLu/1.1Laboratory of Christian Drosten, Laboratory of Marcel A. MüllerN/A;\
RRID: CVCL_RX22MyDauLu/47.1Laboratory of Christian Drosten, Laboratory of Marcel A. MüllerN/A;\
RRID: CVCL_RX18BHK-21Laboratory of Georg HerrlerATCC Cat\# CCL-10;\
RRID:CVCL_1915NIH/3T3Laboratory of Stefan PöhlmannATCC Cat\# CRL-1658;\
RRID:CVCL_0594HAEHTCR Foundation (Human Tissue and Cell Research)N/A293TDSMZCat.\#: ACC-635;\
RRID: CVCL_0063**Oligonucleotides**SARS-2-S (BamHI) F AAGGCCGGATCCGCCACCATGTTTCT\
GCTGACCACCAAGCSigma-AldrichN/ASARS-2-S (XbaI) R AAGGCCTCTAGATTAGGTGTAGTGCAG\
TTTCACGSigma-AldrichN/ASARS-2-S-HA (XbaI) R AAGGCCTCTAGATTACGCATAATCC\
GGCACATCATACGGATAGGTGTAGTGCAGTTTCACGSigma-AldrichN/AWH-Ssyn 651F CAAGATCTACAGCAAGCACACCSigma-AldrichN/AWH-Ssyn 1380F GTCGGCGGCAACTACAATTACSigma-AldrichN/AWH-Ssyn 1992F CTGTCTGATCGGAGCCGAGCACSigma-AldrichN/AWH-Ssyn 2648F TGAGATGATCGCCCAGTACACSigma-AldrichN/AWH-Ssyn 3286F GCCATCTGCCACGACGGCAAAGSigma-AldrichN/A**Recombinant DNA**Synthetic, codon-optimized (humanized) SARS-2-SThermoFisher Scientific (GeneArt)N/APlasmid: pCG1-SARS-S([@bib21])N/APlasmid:pCG1-SARS-S-HAThis paperN/APlasmid: pCG1-SARS-2-SThis paperN/APlasmid: pCG1-SARS-2-S-HAThis paperN/APlasmid: pCAGGS-229E-S([@bib24])N/APlasmid: pCAGGS-MERS-S([@bib14])N/APlasmid: pCAGGS-VSV-G([@bib5])N/APlasmid: pCAGGS-NiV-FLaboratory of Andrea MaisnerN/APlasmid: pCAGGS-NiV-GLaboratory of Andrea MaisnerN/APlasmid: pCG1-hACE2([@bib21])N/APlasmid: pCG1-batACE2([@bib21])N/APlasmid: pCG1-hAPN([@bib22])N/APlasmid: pQCXIP-DsRed-hDPP4([@bib30])N/APlasmid: pQCXIBL-hTMPRSS2([@bib30])N/APlasmid: pCG1Laboratory of Roberto CattaneoN/APlasmid: pCAGGS-DsRedLaboratory of Stefan PöhlmannN/APlasmid: pCAGGS-eGFPLaboratory of Stefan PöhlmannN/A**Software and Algorithms**Hidex Sense Microplate Reader SoftwareHidex Deutschland Vertrieb GmbH<https://www.hidex.de/>ChemoStar Imager Software (version v.0.3.23)Intas Science Imaging Instruments GmbH<https://www.intas.de/>MEGA 7.0.26[@bib62]<https://www.megasoftware.net>Adobe Photoshop CS5 Extended (version 12.0 × 32)Adobe<https://www.adobe.com/>GraphPad Prism (version 8.3.0(538))GraphPad Software<https://www.graphpad.com/>Microsoft Office Standard 2010 (version 14.0.7232.5000)Microsoft Corporation<https://products.office.com/>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Requests for material can be directed to Markus Hoffmann (<mhoffmann@dpz.eu>) and the lead contact, Stefan Pöhlmann (<spoehlmann@dpz.eu>). All materials and reagents will be made available upon installment of a material transfer agreement (MTA).

Experimantal Model and Subject Details {#sec4.3}
--------------------------------------

### Cell cultures, primary cells, viral strains {#sec4.3.1}

All cell lines were incubated at 37°C and 5% CO~2~ in a humidified atmosphere. 293T (human, kidney), BHK-21 (Syrian hamster, kidney cells), Huh-7 (human, liver), LLC-PK1 (pig, kidney), MRC-5 (human, lung), MyDauLu/47.1 (Daubenton's bat \[*Myotis daubentonii*\], lung), NIH/3T3 (Mouse, embryo), RhiLu/1.1 (Halcyon horseshoe bat \[*Rhinolophus alcyone*\], lung) and Vero (African green monkey, kidney) cells were incubated in Dulbecco's' modified Eagle medium (PAN-Biotech). Calu-3 (human, lung), Caco-2 (human, colon), MDBK (cattle, kidney) and MDCKII (Dog, kidney) cells were incubated in Minimum Essential Medium (ThermoFisher Scientific). A549 (human, lung), BEAS-2B (human, bronchus) and NCI-H1299 (human, lung) cells were incubated in DMEM/F-12 Medium with Nutrient Mix (ThermoFisher Scientific). Vero cells stably expressing human TMPRSS2 were generated by retroviral transduction and blasticidin-based selection. All media were supplemented with 10% fetal bovine serum (Biochrom), 100 U/mL of penicillin and 0.1 mg/mL of streptomycin (PAN-Biotech), 1x non-essential amino acid solution (10x stock, PAA) and 10 mM sodium pyruvate (ThermoFisher Scientific). For seeding and subcultivation, cells were first washed with phosphate buffered saline (PBS) and then incubated in the presence of trypsin/EDTA solution (PAN-Biotech) until cells detached. Transfection was carried out by calcium-phosphate precipitation. Lung tissue samples were obtained and experimental procedures were performed within the framework of the non-profit foundation HTCR, including the informed patient's consent.

For preparation of human airway epithelial cells, bronchus tissue was derived from patients undergoing pulmonary resection and was provided by the Biobank of the Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians- University Munich. Primary human airway epithelial cells were subsequently isolated as described ([@bib54]). In brief, tissue with a length of approximately 10 mm and a diameter of 8mm was collected and incubated for 24 h at 4°C with DMEM (GIBCO) containing 1 mg/mL protease type XIV and 10 μg/mL DNase I, 100 units/mL penicillin and 100 μg/mL streptomycin, 2.5 μg/mL amphotericin B, and 50 μg/mL gentamicin (GIBCO). The epithelial cells were then harvested from the mucosal surface using the scalpel and were resuspended in growth medium. After incubation at 37°C, 5% CO~2~ for 2 h to remove adherent fibroblast cells, non-adherent cells were seeded on a collagen I coated flask and maintained at 37°C, 5% CO~2~. The growth medium was refreshed every 2 days and consisted of a 1:1 mixture of DMEM (GIBCO) and Airway Epithelial Cell basal medium (Promocell, Heidelberg, Germany) supplemented with 52 μg/mL bovine pituitary extract, 15 ng/mL retinoic acid, 5μg/mL insulin, 0.5 μg/mL hydrocortisone, 0.5 μg/mL epinephrine, 10 μg/mL transferrin, 1 ng/mL human epidermal growth factor (Corning), 1.5 ng/mL bovine serum albumin, 100 units/mL penicillin and 100 μg/mL streptomycin, with or without 5 μM Rho-associated protein kinase inhibitor (Y-27632), as previously described ([@bib54]). If not stated otherwise all materials were purchased from Sigma-Aldrich.

For infection experiments with SARS-CoV-2, the SARS-CoV-2 isolate Munich 929 was propagated in VeroE6 cells (passage 1) after primary isolation from patient material on Vero-TMPRSS2 cells (passage 0).

Method Details {#sec4.4}
--------------

### Plasmids {#sec4.4.1}

Expression plasmids for vesicular stomatitis virus (VSV, serotype Indiana) glycoprotein (VSV-G), Nipah virus (NiV) fusion (F) and attachment glycoprotein (G), SARS-S (derived from the Frankfurt-1 isolate) with or without a C-terminal HA epitope tag, HCoV-229E-S, MERS-S, human and bat angiotensin converting enzyme 2 (ACE2), human aminopeptidase N (APN), human dipeptidyl-peptidase 4 (DPP4) and human TMPRSS2 have been described elsewhere ([@bib2], [@bib5], [@bib14], [@bib21], [@bib24], [@bib31]). For generation of the expression plasmids for SARS-2-S with or without a C-terminal HA epitope tag we PCR-amplified the coding sequence of a synthetic, codon-optimized (for human cells) SARS-2-S DNA (GeneArt Gene Synthesis, ThermoFisher Scientific) based on the publicly available protein sequence in the National Center for Biotechnology Information database (NCBI Reference Sequence: YP_009724390.1) and cloned in into the pCG1 expression vector via BamHI and XbaI restriction sites.

### Pseudotyping of VSV and transduction experiments {#sec4.4.2}

For pseudotyping, VSV pseudotypes were generated according to a published protocol ([@bib1]). In brief, 293T transfected to express the viral surface glycoprotein under study were inoculated with a replication-deficient VSV vector that contains expression cassettes for eGFP (enhanced green fluorescent protein) and firefly luciferase instead of the VSV-G open reading frame, VSV^∗^ΔG-fLuc (kindly provided by Gert Zimmer, Institute of Virology and Immunology, Mittelhäusern/Switzerland). After an incubation period of 1 h at 37°C, the inoculum was removed and cells were washed with PBS before medium supplemented with anti-VSV-G antibody (I1, mouse hybridoma supernatant from CRL-2700; ATCC) was added in order to neutralize residual input virus (no antibody was added to cells expressing VSV-G). Pseudotyped particles were harvested 16 h postinoculation, clarified from cellular debris by centrifugation and used for experimentation.

For transduction, target cells were grown in 96-well plates until they reached 50%--75% confluency before they were inoculated with respective pseudotyped VSV. For experiments addressing receptor usage, cells were transfected with expression plasmids 24 h before transduction. In order to block ACE2 on the cell surface, cells were pretreated with 2 or 20 μg/mL anti-ACE2 antibody (R&D Systems, goat, AF933). As control, an unrelated anti-DC-SIGN antibody (Serotec, goat, 20 μg/mL) was used. For experiments involving ammonium chloride (final concentration 50 mM) and protease inhibitors (E-64d, 25 μM; camostat mesylate, 1-500 μM), target cells were treated with the respective chemical 2 h before transduction. For neutralization experiments, pseudotypes were pre-incubated for 30 min at 37°C with different serum dilutions. Transduction efficiency was quantified 16 h posttransduction by measuring the activity of firefly luciferase in cell lysates using a commercial substrate (Beetle-Juice, PJK) and a Hidex Sense plate luminometer (Hidex).

### Quantification of cell viability {#sec4.4.3}

Cell viability following treatment of Calu-3 cells with camostat mesylate was analyzed using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). In brief, Calu-3 cells grown to 50% confluency in 96-well plates were incubated for 24 h in the absence or presence of different concentrations (1-500 μM) of camostat mesylate. Next, the culture medium was aspirated and 100 μl of fresh culture medium was added before an identical volume of the assay substrate was added. Wells containing only culture medium served as a control to determine the assay background. After 2 min of incubation on a rocking platform and additional 10 min without movement, samples were transferred into white opaque-walled 96-well plates and luminescent signal were recorded using a Hidex Sense plate luminometer (Hidex).

### Analysis of SARS-2-S expression and particle incorporation {#sec4.4.4}

To analyze S protein expression in cells, 293T cells were transfected with expression vectors for HA-tagged SARS-2-S or SARS-S or empty expression vector (negative control). The culture medium was replaced at 16 h posttransfection and the cells were incubated for an additional 24 h. Then, the culture medium was removed and cells were washed once with PBS before 2x SDS-sample buffer (0.03 M Tris-HCl, 10% glycerol, 2% SDS, 0.2% bromophenol blue, 1 mM EDTA) was added and cells were incubated for 10 min at room temperature. Next, the samples were heated for 15 min at 96°C and subjected to SDS-PAGE and immunoblotting.

For analysis of S protein incorporation into pseudotyped particles, 1 mL of the respective VSV pseudotypes were loaded onto a 20% (w/v) sucrose cushion (volume 50 μl) and subjected to high-speed centrifugation (25.000 g for 120 min at 4°C). Thereafter, 1 mL of supernatant was removed and the residual volume was mixed with 50 μl of 2x SDS-sample buffer, heated for 15 min at 96°C and subjected to SDS-PAGE and immunoblotting. After protein transfer, nitrocellulose membranes were blocked in 5% skim milk solution (5% skim milk dissolved in PBS containing 0.05% Tween-20, PBS-T) for 1 h at room temperature and then incubated over night at 4°C with the primary antibody (diluted in in skim milk solution)). Following three washing intervals of 10 min in PBS-T the membranes were incubated for 1 h at room temperature with the secondary antibody (diluted in in skim milk solution), before the membranes were washed and imaged using an in in house-prepared enhanced chemiluminescent solution (0.1 M Tris-HCl \[pH 8.6\], 250 μg/mL luminol, 1 mg/mL para-hydroxycoumaric acid, 0.3% H~2~O^2^) and the ChemoCam imaging system along with the ChemoStar Professional software (Intas Science Imaging Instruments GmbH). The following primary antibodies were used: Mouse anti-HA tag (Sigma-Aldrich, H3663, 1:2,500), mouse anti-β-actin (Sigma-Aldrich, A5441, 1:2,000), mouse anti-VSV matrix protein (Kerafast, EB0011, 1:2,500). As secondary antibody we used a peroxidase-coupled goat anti-mouse antibody (Dianova, 115-035-003, 1:10000).

### Infection with authentic SARS-CoV-2 {#sec4.4.5}

BHK-21 cells (1.6 x10^5^ cells/mL) were transfected with ACE2 and DsRed as a negative control. After 24 h, cells were washed with PBS and infected with 8x10^7^ genome equivalents (GE) per 24-well of SARS-CoV-2 isolate Munich 929 for 1 h at 37°C. Calu-3 cells (5 x10^5^ cells/mL) were mock treated or treated with 100 μM camostat mesylate (Sigma Aldrich) 2 h prior to infection with SARS-CoV-2 isolate Munich 929 at a multiplicity of infection (MOI) of 0.001 for 1 h at 37°C. After infection, cells were washed three times with PBS before 500 μl of DMEM medium was added. At 16 or 24 h post infection, 50 μl culture supernatant was subjected to viral RNA extraction using a viral RNA kit (Macherey-Nagel) according to the manufacturer's instructions. GE per ml were detected by real time RT-PCR using a previously reported protocol ([@bib9]).

### Sera {#sec4.4.6}

The convalescent human anti-SARS-CoV sera (CSS-2 to CSS-5) stemmed from the serum collection of the national consiliary laboratory for coronavirus diagnostics at Charité, Berlin, Germany or the Robert Koch Institute, Berlin, Germany. All sera were previously tested positive using a recombinant S-based immunofluorescence test ([@bib6]). CSS-2 was taken from a SARS patient 3.5 years post onset of disease. CSS-3 and CSS-4 originated from a second SARS patient 24 and 36 days post onset of disease. CSS-5 was collected from a third SARS patient 10 days post onset of disease. Rabbit sera were obtained by immunizing rabbits with purified SARS-S1 protein fused to the Fc portion of human immunoglobulin.

### Phylogenetic analysis {#sec4.4.7}

Phylogenetic analysis (neighbor-joining tree, bootstrap method with 5,000 iterations, Poisson substitution model, uniform rates among sites, complete deletion of gaps/missing data) was performed using the MEGA7.0.26 software. Reference sequences were obtained from the National Center for Biotechnology Information and GISAID (Global Initiative on Sharing All Influenza Data) databases. Reference numbers are indicated in the figures.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

One-way or two-way analysis of variance (ANOVA) with Dunnett posttest was used to test for statistical significance. Only p values of 0.05 or lower were considered statistically significant (p \> 0.05 \[ns, not significant\], p ≤ 0.05 \[^∗^\], p ≤ 0.01 \[^∗∗^\], p ≤ 0.001 \[^∗∗∗^\]). For all statistical analyses, the GraphPad Prism 7 software package was used (GraphPad Software).

Data and Code Availability {#sec4.6}
--------------------------

The study did not generate unique datasets or code.
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